Mynewsdesk LinkedIn

The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®.

Affibodys latest Press releases

To the archive

2022-11-08

Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence 2022

Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence...[read more]

2022-11-07

Affibody’s partner Rallybio Announces Positive Phase 1 Results for RLYB116...[read more]

2022-06-03

Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2...[read more]

Affibody’s proprietary technology offers several key advantages over current targeted approaches

Research & Development

Multi-specific formats enabling bi-specific binding and extended half-life

Site-specifically modified drug conjugates with excellent tox profile and high tumor uptake

Biodistribution flexibility and good tissue penetration to reach targets that are difficult to reach for antibodies